Brief: Vir Biotechnology Q2 Cash & Investments USD 1,430 Million
01/08/2024 21:02
Aug 01 (Reuters) - Vir Biotechnology Q2 revenue USD 3.1 million vs. IBES estimate USD 7.5 million
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO